DOES AN IMMUNOSCINTIGRAPHY WITH OC-125 AFFECT THE PROGNOSIS OF OVARIAN-CANCER

In a retrospective study, a total of 120 ovarian cancer patients were paired in terms of staging, grading, patent age, and operative and cyt ostatic therapy. Half of the patients underwent radioimmunoscintigraph y for diagnostic purposes. From the point of view of possible adjuvant immunological therapy, we investigated to what extent patients with t reated ovarian cancer benefit from the application of OC 125 in terms of survival time. In our study we have been able to show that at favor able stages (FIGO II) the patient benefitted more from a radioimmunosc intigraphy thant at prognostically unfavorable stages (FIGO IV). Even within FIGO stage III we have been able to show, thanks to the large n umber of cases, that patients with an NED situation benefitted signifi cantly more form radioimmunoscintigraphy in terms of survival than tho se with residual tumors. Throughout FIGO stage III, patients with radi oimmunoscintigraphy showed significantly superior 5-year survival rate s (p<0.05) than those without radioimmunoscintigraphy. These data woul d appear to justify prospective studies to establish to what extent ov arian cancer patients benefit from an adjuvant application of OC 125 i n terms of the 5-years survival rate and the relapse-free interval.